Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transdermal vs Subcutaneous Teriparatide in Postmenopausal Osteoporosis
NCT01011556Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2009
- Primary completion
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of teriparatide in postmenopausal osteoporosis (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 months. Started Nov 2009; status: completed.
02
Drugs
teriparatide
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT01011556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01011556.